Neurocrine Biosciences | NBIX
Stock Price
125.65
Daily Change
0.65 0.52%
Monthly
9.18%
Yearly
12.02%
Q4 Forecast
120.04


Peers Price Chg Day Year Date
AbbVie 177.16 5.32 3.10% 27.76% Nov/22
Acadia Pharmaceuticals 16.37 0.19 1.17% -26.56% Nov/22
Agios Pharmaceuticals 55.68 0.14 0.25% 149.35% Nov/22
ALKERMES 28.78 1.08 3.90% 18.00% Nov/22
Alnylam Pharmaceuticals 244.89 -1.91 -0.77% 50.31% Nov/22
Amgen 294.64 4.72 1.63% 10.99% Nov/22
Biogen 157.88 -0.16 -0.10% -31.93% Nov/22
BioMarin Pharmaceutical 64.26 0.81 1.28% -27.13% Nov/22
Cytokinetics 49.10 1.43 3.00% 53.58% Nov/22
Dynavax Technologies 12.42 0.06 0.49% -8.41% Nov/22
Exelixis 35.61 0.78 2.24% 64.25% Nov/22
Gilead Sciences 90.01 0.40 0.45% 19.41% Nov/22
Halozyme Therapeutics 49.00 3.30 7.22% 21.35% Nov/22
Incyte 71.72 1.33 1.89% 33.46% Nov/22
Ionis Pharmaceuticals 34.01 0.07 0.21% -31.75% Nov/22
Intra Cellular Therapies 85.69 0.24 0.28% 44.21% Nov/22
Neurocrine Biosciences 125.65 0.65 0.52% 12.02% Nov/22
Pfizer 25.66 0.56 2.23% -15.87% Nov/22
Prothena 14.60 0.16 1.11% -56.01% Nov/22
Ultragenyx Pharmaceutical 47.24 1.22 2.65% 20.69% Nov/22
Regeneron Pharmaceuticals 738.00 -5.43 -0.73% -7.55% Nov/22
Repligen 142.58 0.82 0.58% -11.87% Nov/22
Sarepta Therapeutics 114.23 3.73 3.38% 37.84% Nov/22
Teva Pharmaceutical Industries 6,340.00 20.00 0.32% 78.99% Nov/21
Vertex Pharmaceuticals 451.02 0.87 0.19% 27.75% Nov/22

Indexes Price Day Year Date
USND 19004 31.23 0.16% 33.35% Nov/22
US2000 2407 42.65 1.80% 33.15% Nov/22

Neurocrine Biosciences traded at $125.65 this Friday November 22nd, increasing $0.65 or 0.52 percent since the previous trading session. Looking back, over the last four weeks, Neurocrine Biosciences gained 9.18 percent. Over the last 12 months, its price rose by 12.02 percent. Looking ahead, we forecast Neurocrine Biosciences to be priced at 120.04 by the end of this quarter and at 115.66 in one year, according to Trading Economics global macro models projections and analysts expectations.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.